YWHAQ and demyelinating disease: Systemically delivered LIF promotes the functional recovery of oligodendrocytes from stroke by peroxiredoxin IV,43 protects oligodendrocytes against proinflammatory cytokine-induced apoptosis by inducing the expression of the antiapoptotic protein 14-3-3,44 and protects oligodendrocytes in a murine experimental autoimmune encephalomyelitis model independent of inflammatory cytokine modulation.11 Oligodendrocyte precursor cell–targeted LIF nanoparticle therapy has shown promise in the lysolecithin model of demyelinating disease.45